.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Chinese Patent Office
Cipla
McKinsey
Express Scripts
Accenture
Daiichi Sankyo
QuintilesIMS
Farmers Insurance

Generated: September 25, 2017

DrugPatentWatch Database Preview

VIEKIRA PAK (COPACKAGED) Drug Profile

« Back to Dashboard

What is the patent landscape for Viekira Pak (copackaged), and what generic Viekira Pak (copackaged) alternatives are available?

Viekira Pak (copackaged) is a drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has four hundred and eighty-two patent family members in fifty-one countries.

The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir profile page.

Summary for Tradename: VIEKIRA PAK (COPACKAGED)

Patents:18
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list9
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:VIEKIRA PAK (COPACKAGED) at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: VIEKIRA PAK (COPACKAGED)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIEKIRA PAK (COPACKAGED)

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,969,357Methods for treating HCV► Subscribe
6,894,171 Polymorph of a pharmaceutical► Subscribe
8,993,578Methods for treating HCV► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
8,333,990Solid pharmaceutical dosage form► Subscribe
8,025,899Solid pharmaceutical dosage form► Subscribe
8,716,454Solid compositions► Subscribe
8,193,367Polymorph of a pharmaceutical► Subscribe
9,309,279Macrocyclic hepatitis C serine protease inhibitors► Subscribe
9,676,797Anti-viral compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIEKIRA PAK (COPACKAGED)

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2013059638► Subscribe
Taiwan201204713► Subscribe
Canada2828495► Subscribe
China101163479► Subscribe
South Korea20070114294► Subscribe
Guatemala201100056A► Subscribe
Canada2893379► Subscribe
Spain2529144► Subscribe
Guatemala200600295► Subscribe
Slovenia2692346► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIEKIRA PAK (COPACKAGED)

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00015Denmark► SubscribePRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150119
0729Netherlands► SubscribePRODUCT NAME: DASABUVIR OF ZOUT DAARVAN, WAARONDER DASABUVIR NATRIUMMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/14/983 20150119
2015013Lithuania► SubscribePRODUCT NAME: DASABUVIRUM; REGISTRATION NO/DATE: EU/1/14/983 20150115
0150015 00143Estonia► SubscribePRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015
15/010Ireland► SubscribePRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
0730Netherlands► SubscribePRODUCT NAME: PARITAPREVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119
2015013,C2203431Lithuania► SubscribePRODUCT NAME: DASABUVIRAS; REGISTRATION NO/DATE: EU/1/14/983 20150115
7 50008-2015Slovakia► SubscribePRODUCT NAME: DASABUVIR (VO FORME MONOHYDRATU SODNEJ SOLI); REGISTRATION NO/DATE: EU/1/14/983/001 20150119
2015000042Germany► SubscribePRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
0150019 00156Estonia► SubscribePRODUCT NAME: PARITAPREVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Baxter
Harvard Business School
Cantor Fitzgerald
US Army
McKinsey
Julphar
UBS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot